Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Drug Triggers Liver Regeneration After Surgery

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Print article
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice.

Liver cancer often results in a loss of blood flow, and consequently, oxygen and nutrients to the liver tissue, resulting in deteriorating liver function. Although the diseased part of the liver can often be surgically removed, the sudden restoration of blood flow to the remaining liver tissue can trigger inflammation—a process called ischemia reperfusion injury (IRI). IRI occurs partly from the deposition of immune proteins called complement on the surface of liver cells, causing them to die and thereby impairing liver regeneration.

Complement inhibitors effectively suppress IRI, but the benefits of this approach come at a cost, because specific complement proteins are also required for liver tissue to regrow. According to scientists from the Medical University of South Carolina (MUSC; Charleston, USA), the novel inhibitor suppressed the deposition of complement proteins and promoted the division of new liver cells. Even after removal of as much as 90% of the liver, treatment increased survival from 0% in untreated animals to an impressive 70%. The study’s findings were published August 11, 2014, in the Journal of Experimental Medicine.

The selectivity of this unique complement inhibitor, and its unforeseen ability to enhance liver regeneration, suggests that it might represent a new treatment strategy for a range of liver injuries in humans, according to the researchers.

Related Links:

Medical University of South Carolina



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.